DDReg Pharma

DELIVER BETTER DATA TO ENSURE FASTER APPROVAL
DDReg Pharma

Author name: development

banner_image

Increasing Harmonization for Complex Generics

Regulatory agencies across the globe are increasing their efforts in advancing the development of complex generics to facilitate patient and/or consumer access to safe, efficacious, and high-quality generic medicines. The generic medicine industry is already associated with many challenges such as declining profit margins and pricing making it a less attractive industry for generic pharmaceutical …

Increasing Harmonization for Complex Generics Read More »

Strengthening Safety Compliance in Somalia

The National Medicine Regulatory Authority (NMRA) of the Ministry of Health regulates and controls regulatory & safety related operations for pharmaceuticals in Somalia. It is responsible for facilitating the availability and accessibility of safe and effective medicines to the Somalian population. More recently, the Somalian NMRA issued their very first Somali Pharmacovigilance Guideline with the …

Strengthening Safety Compliance in Somalia Read More »

Ensuring Viral Safety of Biotechnology Products

Biotechnology products that are derived from cell lines are associated with a certain degree or risk of viral contamination. These risks can be attributed to source cell line contaminations or exogenous introduction of adventitious virus; indeed these risks need to be reduced as contamination can have major consequences. Virus testing programs have supported in assuring …

Ensuring Viral Safety of Biotechnology Products Read More »

Regulatory Roadmap for Access to MedTech

In an era driven by technological advancements, particularly in healthcare, the need to implement a robust regulatory framework is more than ever to ensure compliance and patient safety. Indeed technological disruptors such as implantable medical devices, artificial intelligence, software, and diagnostics play a crucial role in healthcare whether they facilitate early detection or prevent complex …

Regulatory Roadmap for Access to MedTech Read More »

Fostering Medical Innovation with Expedited Review Processes

2023 marked a significant year in the pharmaceutical industry as the Center for Drug Evaluation and Research (CDER) of the US Food and Drug Administration (FDA) approved an impressive 55 novel drugs. These approvals, including new molecular entities (NMEs) and new therapeutic biologics, underscore the FDA’s commitment to advancing patient care with innovative therapies. Over …

Fostering Medical Innovation with Expedited Review Processes Read More »

Easing Requirements for Minimal Risk Clinical Trials

Expediting clinical trials that post minimal risk is important to advance healthcare & drug development. In particular, easing the requirements for informed consent regarding trial participants- for minimal risk clinical trials- can help expedite the entire clinical development process and ultimately accelerate the overall regulatory approval process. Earlier the US FDA’s regulations allowed for exceptions …

Easing Requirements for Minimal Risk Clinical Trials Read More »

Standardizing Real World Data for Drug and Biological Product Submissions

Real world data (RWD) is proving to be an important source of information for applications such as New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), biologic license applications (BLAs) and Investigational New Drug (IND) applications. With RWD being submitted as relevant “study data”, certain agencies like the US FDA, require that the format should …

Standardizing Real World Data for Drug and Biological Product Submissions Read More »

Streamlining Clinical Investigations for Medical Devices

Clinical investigations for medicinal devices are critical in order to advance healthcare and patient safety. Streamlining clinical investigations help accelerate the delivery of innovative solutions to patients, which ensures timely access to devices that would help diagnose and treat diseases. Simplifying regulatory processes, enhancing stakeholder engagement, and aligning with global practices fosters more rapid approvals. …

Streamlining Clinical Investigations for Medical Devices Read More »

DDReg Managing Director wins ET RE Pharma “Woman Icon of the Year” Award 2024

The 4th edition of the Economic Times (ET) RE Pharma Awards was held on the 20th of January 2024 to recognize excellence within the Indian Pharmaceutical Industry. Indeed, these awards have developed into a prestigious platform to celebrate the outstanding achievements by stakeholders in the pharmaceutical sector of India- both, organizations, and individuals. Continuing its …

DDReg Managing Director wins ET RE Pharma “Woman Icon of the Year” Award 2024 Read More »

Third Party Review Program for Medical Devices

The onset of the pandemic highlighted many obstacles pertaining to medical devices used to detect and diagnose the virus, SARS-CoV-2. Many device manufacturers emerged with their concerns and requested for “Emergency-Use Authorization” (EUA) for their in vitro diagnostic medical devices used to help detect the virus. In response to this request, the US FDA provided …

Third Party Review Program for Medical Devices Read More »